Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 483-493

  Sandborn, W J ^a   Colombel, J F ^b   D'Haens, G ^c   Plevy, S E ^d   Panes J ^e   Robinson, A M ^f   Pollack, P F ^f   Zhou, Q ^f   Castillo, M ^f   Thakkar, R B ^f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f ABBVIE INC   (United States)

Author keywords

Adalimumab; C reactive protein; Clinical remission; Crohn's disease; Dose

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO;

ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876239031     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.779575     Document Type: Article

References (25)

1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33, quiz 591
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
3. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
4. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
5. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 349-58
6. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-46
7. Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of antitumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2011;9:395-9
8. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40
9. Sandborn WJ, Colombel J-F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011;17:141-51
10. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54
11. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54
12. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7
13. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5
14. Humira [package insert]. North Chicago, IL, USA: Abbott Laboratories, 2011
15. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28
16. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
18. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84
19. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012;35:335-41
20. Chaparro M, Panes J, Garcia V, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012;18:685-90
21. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013;7:213-221
22. Humira [Summary of Product Characteristics]. Wiesbaden, Germany: Abbott Biotechnology Deutschland GmbH, 2012
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21
24. Vetterlein OM, Nesbitt AM, Stephens S. Antibodies to certolizumab pegol in patients with Crohn's disease do not cross-react with adalimumab, etanercept, or infliximab. Gastroenterology 2007;132(4 Suppl 1): AA-556
25. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-6